Article
Multidisciplinary Sciences
Chelsey M. VanDrisse, Rosalie Lipsh-Sokolik, Olga Khersonsky, Sarel J. Fleishman, Dianne K. Newman
Summary: This study demonstrates that by engineering the structure of PodA protein and combining it with tobramycin, the killing effect on P. aeruginosa can be enhanced, especially on biofilms that are resistant to conventional antibiotic treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Infectious Diseases
Karan Gandhi, Shiv Dhiman, Rajat Arora, Danzel Marie Ramirez, Danyel Ramirez, Gilbert Arthur, Frank Schweizer
Summary: Metal ions, including Fe3+, influence the binding of antibiotics and the uptake of antibiotics by bacteria. Amphiphilic tobramycins, a new class of antibiotic potentiators, synergize with various antibiotics against Gram-negative bacteria. In this study, iron-deferoxamine conjugates were prepared and tested for their antibacterial activity and synergistic effects with antibiotics. The conjugates showed strong synergistic effects with outer-membrane-impermeable antibiotics and selectively improved the susceptibility of multidrug-resistant bacteria to tetracyclines. However, the antibiotic potentiating effect was not influenced by the Fe3+ concentration.
Article
Pharmacology & Pharmacy
Nuoyan Wang, Xuemin Chen, Jing Luo, Fei Deng, Fuguo Shi, Qin Wu, Yasi Huang, Qin Ouyang, Rongxin Qin, Hong Zhou
Summary: This study investigated the antibacterial sensitization effect of DHA27 combined with tobramycin in tobramycin-resistant Pseudomonas aeruginosa. The combination showed significant antibacterial effects on many resistant strains and reduced bacterial load in the spleen and lungs in a mouse model. The study also revealed that the effect was related to the inhibition of mRNA expression of aminoglycoside-modifying enzymes.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Roberta Genova, Pablo Laborda, Trinidad Cuesta, Jose Luis Martinez, Fernando Sanz-Garcia
Summary: Understanding the consequences of drug resistance in bacterial physiology is crucial for exploiting its weaknesses. Collateral sensitivity, a potentially exploitable phenotype, may not be conserved among different isolates. Identifying robust and conserved collateral sensitivity patterns is important for translating this knowledge into clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Microbiology
Devin Sindeldecker, Shaurya Prakash, Paul Stoodley
Summary: This study analyzed the zone of killing (ZOK) in Pseudomonas aeruginosa biofilms using both in vitro and in silico methods. The findings revealed that achieving a specific antibiotic concentration versus time constraint (AUC) could completely eradicate bacteria in the biofilms. This suggests that appropriate antibiotic concentrations and treatment duration may be effective against antibiotic-resistant and -tolerant biofilm infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Rhea G. Abisado-Duque, Kade A. Townsend, Brielle M. Mckee, Kathryn Woods, Pratik Koirala, Alexandra J. Holder, Vaughn D. Craddock, Matthew Cabeen, Josephine R. Chandler
Summary: A gene mutation in Pseudomonas aeruginosa can reverse the selective effects of LasR mutations on antibiotic resistance.
JOURNAL OF BACTERIOLOGY
(2023)
Article
Infectious Diseases
Srikanth Dumpati, Shehzad A. Naroo, Sunil Shah, Debarun Dutta
Summary: This study assessed the antimicrobial activity of a UVC device against microorganisms related to contact lens adverse events. The results showed that UVC exposure had a high antimicrobial efficacy and could be used for lens disinfection.
Article
Respiratory System
Freddy Frost, Gregory R. Young, Laura Wright, Nahida Miah, Darren L. Smith, Craig Winstanley, Martin J. Walshaw, Joanne L. Fothergill, Dilip Nazareth
Summary: This study demonstrates that in adults with CF and P. aeruginosa infection, AZLI + IV performed better in improving lung function and quality of life compared to the current standard treatment.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Biochemistry & Molecular Biology
Gianmarco Mangiaterra, Nicholas Cedraro, Salvatore Vaiasicca, Barbara Citterio, Emanuela Frangipani, Francesca Biavasco, Carla Vignaroli
Summary: Persistent and viable but non-culturable (VBNC) Pseudomonas aeruginosa cells play a major role in the recurrence and non-responsiveness to antibiotics of cystic fibrosis (CF) lung infections. The entry into the VBNC state can be triggered by sub-inhibitory antibiotic concentrations found in the CF lung between therapeutic cycles. Two CF P. aeruginosa isolates were analyzed in this study, and the results suggest that drug efflux, specifically mediated by MexXY efflux pump overexpression, may play a crucial role in the abundance of VBNC cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Ophthalmology
Abdulraouf Ramadan, Zhiyi Cao, Mihaela Gadjeva, Tanweer S. Zaidi, Vijay A. Rathinam, Noorjahan Panjwani
Summary: The purpose of this study was to investigate the role of the NLRP3 inflammasome pathway in clearing Pseudomonas aeruginosa infection in mouse corneas. The results showed that NLRP3(-/-) mice had more severe infection compared to wild type mice. This suggests that activation of the NLRP3 pathway is crucial for clearing Pseudomonas aeruginosa infection.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2023)
Article
Microbiology
Melissa Pitton, Simone Oberhaensli, Fiona Appiah, Jean-Luc Pagani, Anne Fournier, Stephan M. Jakob, Yok-Ai Que, David R. Cameron
Summary: This study reports a case of small-colony variant (SCV) emergence of Pseudomonas aeruginosa in a patient undergoing aminoglycoside treatment for burn wound infection, and confirms the causative role of a single ispA mutation in SCV emergence and increased aminoglycoside resistance. The involvement of IspA in ubiquinone synthesis provides a possible link between electron transport and SCV formation in P. aeruginosa.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Zhenwei Yu, Jianping Zhu, Jiayi Jin, Lingyan Yu, Gang Han
Summary: The use and cost of ocular topical anti-infectives for outpatients in China have been progressively increasing, although the usage rate slightly decreased. Levofloxacin is the most commonly used anti-infective, especially among patients aged between 19 and 45 years old. Tobramycin is more frequently used in pediatric patients, but its overall usage trend is decreasing.
Article
Multidisciplinary Sciences
Silvia M. Caceres, Linda A. Sanders, Noel M. Rysavy, Katie R. Poch, Caroline R. Jones, Kyle Pickard, Tasha E. Fingerlin, Roland A. Marcus, Kenneth C. Malcolm, Jennifer L. Taylor-Cousar, David P. Nichols, Jerry A. Nick, Matthew Strand, Milene T. Saavedra
Summary: This study found that specific genes measured from peripheral blood leukocytes can predict clinical response to inhaled antibiotic therapy in patients with cystic fibrosis. Molecular quantification of systemic inflammation may indicate subgroups of CF patients with variations in underlying inflammation and with variable clinical responses to inhaled antibiotics.
Review
Cardiac & Cardiovascular Systems
J. Stuart Elborn, Francesco Blasi, Charles S. Haworth, Manfred Ballmann, Harm A. W. M. Tiddens, Marlene Murris-Espin, James D. Chalmers, Andre M. Cantin
Summary: Inhaled tobramycin therapy has shown effectiveness in reducing P. aeruginosa microbial density in sputum of bronchiectasis patients, leading to potential clinical benefits such as reduced hospitalizations, exacerbations, and symptoms. Definitive phase 3 trials are needed to determine the clinical efficacy and long-term safety of inhaled tobramycin in bronchiectasis patients with chronic P. aeruginosa infection.
RESPIRATORY MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Sunil Kumar Bose, Karuna Sharma, Sanjay Chhibber, Kusum Harjai
Summary: The study demonstrated that the use of nanolipoidal alpha-terpineol could effectively treat Pseudomonas aeruginosa-induced keratitis, showing significant improvements in bacterial count, corneal pathology, and immunomodulatory effects.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)